JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Clinical trial NCT05998408 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05998408
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Severe Aplastic Anemia Single Lineage Cytopenias, T-LGL Hypoplastic MDS

Start date: 2024-02-20
Primary completion: 2025-07-22
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.